Taiwan and Columbia Purchase COVID-19 Vaccines

Cambridge-based Moderna, Inc. announced supply agreements for the COVID-19 Vaccine Moderna: one with the government of Taiwan for 5 million doses and another with Colombia's government for 10 million doses. Under the terms of the agreements, vaccine deliveries would begin in mid-2021.

“We thank the governments for partnering with us to bring the COVID-19 Vaccine Moderna to Taiwan and Colombia. Both governments have moved quickly to get this done in the face of the pandemic, and we appreciate their collaboration,” said Stéphane Bancel, CEO of Moderna, in a press statement.

The COVID-19 Vaccine Moderna is not currently approved for use in Taiwan or Colombia, and the Company will work with regulators to pursue necessary approvals prior to distribution.

On December 18, 2020, the U.S. FDA authorized the Moderna COVID-19 Vaccine emergency use in individuals 18 years of age or older. Moderna has also received authorization for its COVID-19 vaccine from health agencies in Canada, Israel, the European Union, the United Kingdom, Switzerland, and Singapore.

The COVID-19 Vaccine Moderna is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike protein, which was co-developed by Moderna and investigators from the National Institute of Allergy and Infectious Disease’s Vaccine Research Center.

The FDA states people should not get the Moderna COVID-19 Vaccine if they had a severe allergic reaction after a previous dose of this vaccine or have a severe allergic reaction to any ingredient of this vaccine.